Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain

ATLANTA — The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of treating it also puts the health care system in a bind. Dr. Scott Kahan, director of the National Center for Weight & Wellness and a faculty member at the Johns Hopkins Bloomberg…